Drug Type Synthetic peptide |
Synonyms D-63 153, D-63153, SPI-153 |
Target |
Action antagonists |
Mechanism GnRHR antagonists(Gonadotropin-releasing hormone receptor antagonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization |
Drug Highest PhaseDiscontinuedPhase 3 |
First Approval Date- |
Regulation- |
Molecular FormulaC72H96ClN17O14 |
InChIKeyKATZUZNTRINHDT-HALMFYTRSA-N |
CAS Registry295350-45-7 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Prostatic Hyperplasia | Phase 3 | United States | 01 Jan 2007 | |
Prostatic Cancer | Phase 2 | United States | 01 Nov 2010 | |
Lower Urinary Tract Symptoms | Phase 2 | United States | 23 Jan 2007 | |
Alzheimer Disease | Phase 2 | Germany | - | |
Endometriosis | Preclinical | United States | - |